Actinogen Medical Ltd has released a press release.
Clinical progress for XanaMIA trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
In the deck
Story so far
Earlier from Actinogen Medical
- Actinogen Ethics Committee approval for XanaMIA study
- Response to ASX Price Query
- Strategic Update & Teleconference Call Notification
- Actinogen CEO assumes Managing Director position
- Actinogen appoints Dr Steven Gourlay as CEO
Later from Actinogen Medical
- Actinogen receives positive Pre-IND FDA advice for FXS
- First Patient Enrolled in XanaMIA trial
- Actinogen completes global patent family grant
- Actinogen Medical FY21 Results- Progressing the Pipeline
- R&D Tax Incentive Rebate received of A$1.435 million
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical